{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T12:54:18Z","timestamp":1716555258500},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Novartis Pharma AG, Switzerland"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12931-016-0498-1","type":"journal-article","created":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T04:37:02Z","timestamp":1484109422000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD\u2014a randomised controlled study"],"prefix":"10.1186","volume":"18","author":[{"given":"Joerg","family":"Salomon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiana","family":"Stolz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Domenighetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Georges","family":"Frey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander J.","family":"Turk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Azzola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Sigrist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-William","family":"Fitting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Geiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Wild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Kostikas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Brutsche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,11]]},"reference":[{"key":"498_CR1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.rmed.2015.03.010","volume":"109","author":"A Rossi","year":"2015","unstructured":"Rossi A, Aisanov Z, Avdeev S, Di Maria G, Donner CF, Izquierdo JL, et al. Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. Respir Med. 2015;109:785\u2013802.","journal-title":"Respir Med"},{"key":"498_CR2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1513\/pats.200508-093DO","volume":"3","author":"DE O\u2019Donnell","year":"2006","unstructured":"O\u2019Donnell DE. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3:180\u20134.","journal-title":"Proc Am Thorac Soc"},{"key":"498_CR3","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/15412550600977478","volume":"3","author":"DE O\u2019Donnell","year":"2006","unstructured":"O\u2019Donnell DE, Laveneziana P. The clinical importance of dynamic lung hyperinflation in COPD. COPD. 2006;3:219\u201332.","journal-title":"COPD"},{"key":"498_CR4","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1183\/09031936.00120609","volume":"35","author":"PT Macklem","year":"2010","unstructured":"Macklem PT. Therapeutic implications of the pathophysiology of COPD. Eur Respir J. 2010;35:676\u201380.","journal-title":"Eur Respir J"},{"key":"498_CR5","doi-asserted-by":"crossref","unstructured":"Kostikas K, Siafakas NM. Does the Term \u201cDeflators\u201d Reflect More Accurately the Beneficial Effects of Long-acting Bronchodilators in COPD? COPD. 2016;13:537-9.","DOI":"10.3109\/15412555.2016.1153615"},{"key":"498_CR6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.rmed.2011.09.006","volume":"106","author":"A Rossi","year":"2012","unstructured":"Rossi A, Centanni S, Cerveri I, Gulotta C, Foresi A, Cazzola M, et al. Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium. Respir Med. 2012;106:84\u201390.","journal-title":"Respir Med"},{"key":"498_CR7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2147\/COPD.S51592","volume":"9","author":"W Vincken","year":"2014","unstructured":"Vincken W, Aumann J, Chen H, Henley M, McBryan D, Goyal P. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. Int J Chron Obstruct Pulmon Dis. 2014;9:215\u201328.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"498_CR8","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1586\/17476348.2014.910457","volume":"8","author":"ED Bateman","year":"2014","unstructured":"Bateman ED, Mahler DA, Vogelmeier CF, Wedzicha JA, Patalano F, Banerji D. Recent advances in COPD disease management with fixed-dose long-acting combination therapies. Expert Rev Respir Med. 2014;8:357\u201379.","journal-title":"Expert Rev Respir Med"},{"key":"498_CR9","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejphar.2015.05.020","volume":"761","author":"L Calzetta","year":"2015","unstructured":"Calzetta L, Matera MG, Cazzola M. Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy. Eur J Pharmacol. 2015;761:168\u201373.","journal-title":"Eur J Pharmacol"},{"key":"498_CR10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000368986","volume":"94","author":"G Pelaia","year":"2014","unstructured":"Pelaia G, Maselli R, Matera MG. Treatment of chronic obstructive pulmonary disease by dual bronchodilation with coformulation of indacaterol\/glycopyrronium. Pharmacology. 2014;94:249\u201358.","journal-title":"Pharmacology"},{"key":"498_CR11","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.rmed.2014.01.006","volume":"108","author":"KM Beeh","year":"2014","unstructured":"Beeh KM, Korn S, Beier J, Jadayel D, Henley M, D\u2019Andrea P, et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir Med. 2014;108:584\u201392.","journal-title":"Respir Med"},{"key":"498_CR12","unstructured":"GOLD. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease GOLD 2010. Available from www.goldcopd.com . Accessed 23 June, 2016."},{"key":"498_CR13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.resp.2014.03.012","volume":"197","author":"P Santus","year":"2014","unstructured":"Santus P, Radovanovic D, Henchi S, Di Marco F, Centanni S, D\u2019Angelo E, et al. Assessment of acute bronchodilator effects from specific airway resistance changes in stable COPD patients. Respir Physiol Neurobiol. 2014;197:36\u201345.","journal-title":"Respir Physiol Neurobiol"},{"key":"498_CR14","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1183\/09031936.00200212","volume":"42","author":"ED Bateman","year":"2013","unstructured":"Bateman ED, Ferguson GT, Barnes N, Gallagher N, Green Y, Henley M, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42:1484\u201394.","journal-title":"Eur Respir J"},{"key":"498_CR15","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s12325-015-0218-0","volume":"32","author":"GT Ferguson","year":"2015","unstructured":"Ferguson GT, Flezar M, Korn S, Korducki L, Gronke L, Abrahams R, et al. Efficacy of tiotropium\u2009+\u2009olodaterol in patients with chronic obstructive pulmonary disease by initial disease severity and treatment intensity: a post Hoc analysis. Adv Ther. 2015;32:523\u201336.","journal-title":"Adv Ther"},{"key":"498_CR16","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1183\/09031936.00124013","volume":"43","author":"DA Mahler","year":"2014","unstructured":"Mahler DA, Decramer M, D\u2019Urzo A, Worth H, White T, Alagappan VK, et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur Respir J. 2014;43:1599\u2013609.","journal-title":"Eur Respir J"},{"key":"498_CR17","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1136\/thoraxjnl-2011-201140","volume":"67","author":"DA Mahler","year":"2012","unstructured":"Mahler DA, D\u2019Urzo A, Bateman ED, Ozkan SA, White T, Peckitt C, et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax. 2012;67:781\u20138.","journal-title":"Thorax"},{"key":"498_CR18","unstructured":"Yoshiki I, Kazuyuki C, Akihiro T, Yumeko H, Ryo A, Tomoe F, et al. Add-On Indacaterol Further Improved Lung Function, Airway Resistance, Exercise-Endurance And CAT Score In The COPD Patients Already Treated With Tiotropium. C50 CHRONIC OBSTRUCTIVE PULMONARY DISEASE PHARAMCOTHERAPY: OXYGEN, MECHANISMS, AND REAL LIFE STUDIES. American Thoracic Society International Conference Abstracts: American Thoracic Society; 2013. p. A4368-A."},{"key":"498_CR19","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1164\/rccm.200407-867OC","volume":"171","author":"C Casanova","year":"2005","unstructured":"Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171:591\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"498_CR20","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.rmed.2007.11.004","volume":"102","author":"C Tantucci","year":"2008","unstructured":"Tantucci C, Donati P, Nicosia F, Bertella E, Redolfi S, De Vecchi M, et al. Inspiratory capacity predicts mortality in patients with chronic obstructive pulmonary disease. Respir Med. 2008;102:613\u20139.","journal-title":"Respir Med"},{"key":"498_CR21","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S2213-2600(13)70052-3","volume":"1","author":"JA Wedzicha","year":"2013","unstructured":"Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandstrom T, Taylor AF, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1:199\u2013209.","journal-title":"Lancet Respir Med"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-016-0498-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T07:53:47Z","timestamp":1498377227000},"score":1,"resource":{"primary":{"URL":"http:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-016-0498-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,11]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["498"],"URL":"https:\/\/doi.org\/10.1186\/s12931-016-0498-1","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,11]]},"article-number":"13"}}